We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-17.28%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$222M
AUM Growth
-$86.4M
Cap. Flow
-$22.6M
Cap. Flow %
-10.18%
Top 10 Hldgs %
33.77%
Holding
109
New
40
Increased
8
Reduced
21
Closed
35

Top Buys

1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$11.9M
2
AMGN icon
Amgen
AMGN
+$7.88M
3
GILD icon
Gilead Sciences
GILD
+$7.77M
4
CELG
Celgene Corp
CELG
+$7.45M
5
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$6.84M

Top Sells

1
BIIB icon
Biogen
BIIB
+$12.1M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10M
3
ENDP
Endo International plc
ENDP
+$9.56M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$9.04M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.41M

Sector Composition

1 Healthcare 82.57%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGYP
26
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$3.18M 1.43%
+600,000
New +$4.64M
ATRA icon
27
Atara Biotherapeutics
ATRA
$75.6M
$3.14M 1.42%
4,000
– –
QURE icon
28
uniQure
QURE
$2.77B
$3.07M 1.38%
150,000
-35,000
-19% -$922K
SPNC
29
DELISTED
Spectranetics Corp
SPNC
$2.95M 1.33%
+250,000
New +$4.48M
TXMD icon
30
CALL
TherapeuticsMD
TXMD
$23.8M
$2.93M 1.32%
+10,000
New +$3.55M
BLCM
31
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.91M 1.31%
+20,000
New +$3.67M
CYNA
32
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$2.83M 1.27%
175,000
-87,696
-33% -$1.42M
INCY icon
33
Incyte
INCY
$23.4B
$2.76M 1.24%
+25,000
New +$2.8M
VTAE
34
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$2.75M 1.24%
250,000
-39,200
-14% -$417K
GWPH
35
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.74M 1.23%
30,000
-45,000
-60% -$5M
ACOR
36
DELISTED
Acorda Therapeutics
ACOR
$2.65M 1.19%
+833
New +$3.23M
BCRX icon
37
BioCryst Pharmaceuticals
BCRX
$2.36B
$2.56M 1.15%
225,000
+180,000
+400% +$2.4M
HRTX icon
38
CALL
Heron Therapeutics
HRTX
$89.1M
$2.44M 1.1%
+100,000
New +$3.33M
RLYP
39
DELISTED
RELYPSA INC COM
RLYP
$2.22M 1%
+120,000
New +$3.3M
NBIX icon
40
Neurocrine Biosciences
NBIX
$17.2B
$2.19M 0.98%
55,000
-67,500
-55% -$3.26M
TNXP icon
41
Tonix Pharmaceuticals
TNXP
$198M
– –
0
– –
LRMR icon
42
Larimar Therapeutics
LRMR
$384M
$2.08M 0.93%
+5,417
New +$2.44M
ACHN
43
DELISTED
Achillion Pharmaceuticals
ACHN
$2.07M 0.93%
+300,000
New +$2.44M
NDRM
44
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.07M 0.93%
+100,000
New +$2.05M
PTCT icon
45
CALL
PTC Therapeutics
PTCT
$6.52B
$2M 0.9%
+75,000
New +$3.21M
CLLS
46
Cellectis
CLLS
$265M
$1.98M 0.89%
75,000
-50,000
-40% -$1.67M
EPZM
47
DELISTED
Epizyme, Inc
EPZM
$1.93M 0.87%
150,000
-100,000
-40% -$2.02M
IOVA icon
48
Iovance Biotherapeutics
IOVA
$2.23B
$1.73M 0.78%
300,000
-50,000
-14% -$389K
SAGE
49
DELISTED
Sage Therapeutics
SAGE
$1.73M 0.78%
40,800
-16,700
-29% -$1.03M
ASND icon
50
Ascendis Pharma A/S
ASND
$17.1B
$1.72M 0.77%
97,135
+33,396
+52% +$650K
1
2
3 4 5

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Ghost Tree Capital held 109 positions worth $222M, down 28% from $309M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ghost Tree Capital withdrew a net $22.6M in Q3 2015, closing 35 positions and reducing 21 holdings. Its most notable exit was Biogen, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier, followed by Financials.

Against the trend, Ghost Tree Capital opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $7.67M.

  • Ghost Tree Capital's largest Q3 2015 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 120,000 shares worth $7.67M.
  • Ghost Tree Capital added most to ZELTIQ Aesthetics, Inc. in Q3 2015, an estimated $2.81M increase.
  • Ghost Tree Capital's biggest Q3 2015 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $7M.
  • Ghost Tree Capital fully exited Biogen in Q3 2015, selling an estimated $12.1M.
  • Ghost Tree Capital's ten largest holdings make up 34% of its $222M portfolio in Q3 2015.
  • Ghost Tree Capital opened 40 new positions and closed 35 in Q3 2015.
  • Ghost Tree Capital's portfolio value fell 28% quarter-over-quarter to $222M.

Based on Ghost Tree Capital's 13F filing for Q3 2015, filed 16 Nov 2015.